Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
NovalGen Logo
NovalGen Growth Score
86
CB Rank
268516
Heat Score
61
NovalGen develops breakthrough bispecific therapies for the immune system to fight cancer.
Founded
obfuscation
Private London, England, United Kingdom11-50 www.novalgen.com
Biotechnology
Health Care
Medical
Overview

NovalGen
Growth Score
86
Heat Score
61

Growth Score86
-2 pts
in past quarter
Heat Score 61
9 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About NovalGen

CB Rank
268516
NovalGen develops breakthrough bispecific therapies for the immune system to fight cancer.
Founded
obfuscation
Private London, England, United Kingdom11-50 www.novalgen.com
Biotechnology
Health Care
Medical

Key People

Details

Legal Name NovalGen Ltd
Operating Status Active
Company Type For Profit
Phone Number 44-02071-398639
Contact Email info@novalgen.co.uk
Predictions & Insights

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Key Employee Changes

Products & Services

NVG-111
A bispecific antibody T-cell engager targeting ROR1 for treating hematological malignancies and solid tumors.
NVG-222
A next-generation T cell engager with autoregulation technology, targeting ROR1, designed to reduce toxicity and extend therapeutic window.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 1 Board Members and Advisors 2 Contacts 10

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Sep 17, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 24, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

218
38.85%
 in past month

IT Spend

$198.7KThis year, NovalGen is projected to spend $198.7K on IT, according to Aberdeen.

Active Website Tech Count

NovalGen is actively using the technology Viewport Meta for its website, according to BuiltWith.

Total IP

1NovalGen has 1 registered patent in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is NovalGen's headquarters? NovalGen is located in London, England, United Kingdom.Who are NovalGen's competitors? Alternatives and possible competitors to NovalGen may include Roche, Takeda, and  Amgen.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(790e229 1)
|